2,284 results match your criteria Chorioretinopathy Central Serous


[Central serous chorioretinopathy secondary to Helicobacter pylori: To treat or not to treat, that is the question].

Semergen 2018 Dec 11. Epub 2018 Dec 11.

Grupo EpiChron de Investigación en Enfermedades Crónicas, Instituto Aragonés de Ciencias de la Salud (IACS), ISS Aragón, Zaragoza, España; Centro de Salud Delicias Sur, Zaragoza, España.

View Article
December 2018

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy.

Invest Ophthalmol Vis Sci 2018 Dec;59(15):5924-5931

Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Purpose: To clarify the distinct molecular pathogenesis of central serous chorioretinopathy (CSC) and pachychoroid neovasculopathy (PNV).

Methods: Aqueous humor (AH) was collected from 18 acute CSC, 20 chronic CSC, and 20 PNV patients. Concentrations of 30 cytokines in the AH were analyzed using a multiplex bead immunoassay, and the cytokine profiles were compared among these three groups of patients. Read More

View Article
December 2018

QUANTIFICATION OF CHOROIDAL VASCULATURE BY HIGH-QUALITY STRUCTURE EN FACE SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY IMAGES IN EYES WITH CENTRAL SEROUS CHORIORETINOPATHY.

Retina 2018 Dec 13. Epub 2018 Dec 13.

Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Purpose: To determine the density of the choroidal vasculature by high-quality structure en face optical coherence tomography (OCT) scanned at the same time as OCT angiography in eyes with central serous chorioretinopathy (CSC).

Methods: Thirty-five eyes of 30 patients with CSC (20 men and 10 women; average age, 48.4 years) were studied. Read More

View Article
December 2018
1 Read

Pachychoroid disease of the macula.

Cesk Slov Oftalmol 2018 ;74(1):3-8

Progress in optical coherent tomography (OCT) has recently provided new insights into variety of chorioretinal disorders. The use of EDI (Enhanced Depth Imaging) during OCT examinations and as well as OCT angiography provides a more accurate analysis of the choroid both quantitatively and qualitatively. "Pachychoroid" (greek pachy- [παχύ] - thick) is defined as an abnormal and sustained increase in choroidal thickness 300 μm, which is mainly due to dilated choroidal vessels in the Hallers layer and other structural changes in physiological choroidal architecture. Read More

View Article
January 2018

A two-year study of diffused retinal pigment epitheliopathy treated with half-dose photodynamic therapy guided by simultaneous angiography and optical coherence tomography.

Eye (Lond) 2018 Dec 7. Epub 2018 Dec 7.

Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, 200032, China.

Objectives: Diffused retinal pigment epitheliopathy (DRPE) is not necessarily the same as chronic central serous chorioretinopathy (CSC), but a severe subgroup under the umbrella of chronic CSC. This study was to evaluate the efficacy and safety of half-dose PDT treating DRPE.

Methods: A retrospective case series design was used. Read More

View Article
December 2018

Macular pigment density changes in central serous chorioretinopathy.

Rom J Ophthalmol 2018 Jul-Sep;62(3):222-227

Ophthalmology Department, Bucharest University Emergency Hospital, Bucharest, Romania.

To present a series of 2 cases of central serous chorioretinopathy and the changes in the macular pigment optical density during the evolution of the disease. A 32-year-old patient presented himself for blurred vision on his LE. The SD OCT imaging revealed serous macular detachment of the neurosensory retina on the LE. Read More

View Article
December 2018

The Effect of Intravitreal Bevacizumab on Central Serous Chorioretinopathy.

Med Hypothesis Discov Innov Ophthalmol 2018 ;7(4):176-182

Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.

The aim of this study was to investigate the efficacy of Intravitreal Injection of Bevacizumab (IVB) in patients with Central Serous Chorioretinopathy (CSC) compared to the control group, after four months of injection. In this study, 30 eyes of 30 patients with CSC, who were in the age range of 23 to 50 years old (70% male subject) were included. Eligible patients were randomly allocated to the intervention (n = 15) and control groups (n = 15). Read More

View Article
January 2018

Central serous chorioretinopathy: Current update on management.

Oman J Ophthalmol 2018 Sep-Dec;11(3):200-206

Department of Vitreo-Retina Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.

Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about the pathophysiology of CSC, and hence the diagnosis and management. Multifactorial etiopathology of CSC promotes the use of multiple treatment modalities. Read More

View Article
December 2018
1 Read

Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy.

Clin Exp Ophthalmol 2018 Dec 5. Epub 2018 Dec 5.

Department of Ophthalmology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.

Importance: Analyzing choroidal flow in central serous chorioretinopathy (CSC) with novel device BACKGROUND: To examine the abnormal morphology of choriocapillary flow with optical coherence tomography angiography (OCTA) according to the presence of subretinal fluid (SRF) in CSC.

Design: A hospital-based retrospective study PARTICIPANTS: We analyzed OCTA results of 68 eyes (68 patients) diagnosed as CSC with or without SRF (active and resolved CSC, respectively) at the Asan Medical Center.

Methods: We classified OCTA choriocapillary images into three pattern groups: mixed perfusion, hyper-perfusion, and normal perfusion. Read More

View Article
December 2018

Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy.

Clin Ophthalmol 2018 24;12:2167-2176. Epub 2018 Oct 24.

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands,

Purpose: To describe a spectrum of severe chronic central serous chorioretinopathy (cCSC) cases and their response to photodynamic therapy (PDT).

Patients And Methods: A total of 66 patients (81 eyes) with active severe cCSC were studied, and their response to PDT was compared with a control group consisting of 35 active cCSCs (37 eyes) that did not display characteristics of severity. Best-corrected visual acuity (BCVA) and complete resolution of subretinal fluid (SRF) were considered as main outcome measures. Read More

View Article
October 2018

The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy.

Invest Ophthalmol Vis Sci 2018 Nov;59(13):5682-5692

Department of Ophthalmology, Leiden University Medical Centre, Leiden, The Netherlands.

Purpose: To isolate, culture, and characterize primary human choroidal endothelial cells, and to assess their responsiveness to corticosteroids, in order to enable knowledge gain on the pathogenesis of central serous chorioretinopathy.

Methods: Choroidal endothelial cells were isolated from cadaveric human donors. Magnetic-activated cell sorting with anti-human CD31 was performed for choroidal endothelial cell isolation. Read More

View Article
November 2018
3 Reads

CONVERSION OF FOCAL CHOROIDAL EXCAVATION WITH THE ONSET OF CENTRAL SEROUS CHORIORETINOPATHY: REPORT OF 2 CASES AND REVIEW OF THE LITERATURE.

Retin Cases Brief Rep 2018 Nov 26. Epub 2018 Nov 26.

Departments of Ophthalmology and Visual Sciences, and.

Purpose: To describe two cases of focal choroidal excavation (FCE) conversion in patients with central serous chorioretinopathy.

Methods: Case report and literature review of cases of FCE conversion.

Results: A 35-year-old asymptomatic pregnant patient was found to have conforming FCE on spectral domain optical coherence tomography of the right eye during hydroxychloroquine screening. Read More

View Article
November 2018

Genome-Wide Association Study to Identify a New Susceptibility Locus for Central Serous Chorioretinopathy in the Japanese Population.

Invest Ophthalmol Vis Sci 2018 Nov;59(13):5542-5547

Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.

Purpose: Central serous chorioretinopathy (CSC) is a retinal disorder that often affects the vision of middle-aged people yet the molecular mechanisms of CSC remain unknown. This study was conducted to identify genetic factors influencing individual differences in susceptibility to CSC.

Methods: A two-stage genome-wide association study (GWAS) was conducted with a total of 320 unrelated Japanese idiopathic CSC cases and 3245 population-based controls. Read More

View Article
November 2018
1 Read
3.404 Impact Factor

"Double-layer sign" on spectral domain optical coherence tomography in pachychoroid spectrum disease.

Indian J Ophthalmol 2018 Dec;66(12):1796-1801

NIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK.

Purpose: The "double-layer sign (DLS)" describes the shallow and irregular elevation of the retinal pigment epithelium from the underlying intact Bruch's membrane visualized on the spectral domain optical coherence tomography. In this study, we evaluated the frequency, characteristics of the space within the double layer and other features in the pachychoroid spectrum to aid the clinical diagnosis of these variants.

Methods: This retrospective study evaluated the features of the DLS on multimodal imaging in consecutive patients with a clinical diagnosis of one of the four variants of pachychoroid: pachychoroid pigment epitheliopathy (PPE), pachychoroid neovasculopathy (PCN), chronic central serous chorioretinopathy (CCSCR), and polypoidal choroidal vasculopathy (PCV). Read More

View Article
December 2018

Choroidal biomarkers.

Indian J Ophthalmol 2018 Dec;66(12):1716-1726

Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

A structurally and functionally intact choroid tissue is vitally important for the retina function. Although central retinal artery is responsible to supply the inner retina, choroidal vein network is responsible for the remaining one-third of the external part. Abnormal choroidal blood flow leads to photoreceptor dysfunction and photoreceptor death in the retina, and the choroid has vital roles in the pathophysiology of many diseases such as central serous chorioretinopathy, age-related macular degeneration, pathologic myopia, Vogt-Koyanagi-Harada disease. Read More

View Article
December 2018
6 Reads
0.930 Impact Factor

Commentary: Management of central serous chorioretinopathy: Looking beyond the eye.

Indian J Ophthalmol 2018 Dec;66(12):1714-1715

Advanced Eye Center, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

View Article
December 2018
1 Read

Management of chronic central serous chorioretinopathy.

Indian J Ophthalmol 2018 Dec;66(12):1704-1714

Smt. Kanuri Santhamma Retina Vitreous Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India.

New treatment modalities for the management of central serous chorioretinopathy (CSC) now exist. While acute CSC generally resolves without the requirement for intervention, chronic CSC has been associated with persistent disruption in visual function. Current treatment approaches include photodynamic therapy, oral aldosterone antagonism and subthreshold multifocal laser. Read More

View Article
December 2018
5 Reads
0.930 Impact Factor

Management of central serous chorioretinopathy: Expert panel discussion.

Indian J Ophthalmol 2018 Dec;66(12):1700-1703

Cole Eye Institute, Cleveland, Ohio, USA.

Central serous chorioretinopathy (CSCR), one of the most common diseases in retina clinics, needs a special attention by retina specialists. Considering the challenges in diagnosis, classification, and management of this enigmatic disease and lack of level 1 evidence, there is a need for consensus with regard to establishing management protocols. Read More

View Article
December 2018
1 Read

Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy.

Ophthalmic Genet 2018 Dec 15;39(6):714-716. Epub 2018 Nov 15.

a Department of Ophthalmology , Medical University of Graz , Graz , Austria.

Background: Central serous chorioretinopathy (CSC) is a common chorioretinal disease, characterized by choroidal hyperpermeability leading to neurosensory and/or retinal pigment epithelial detachments. Hypofibrinolysis due to higher plasma concentrations of plasminogen activator type 1 (PAI-1) or lower activity of tissue-type plasminogen activator (t-PA) has been implicated in the pathogenesis of CSC. Functional polymorphisms in the PAI-1 (SERPINE1) and t-Pa (PLAT) are thus potential risk factors for CSC. Read More

View Article
December 2018
1 Read

How ERAP1 and ERAP2 Shape the Peptidomes of Disease-Associated MHC-I Proteins.

Front Immunol 2018 30;9:2463. Epub 2018 Oct 30.

Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain.

Four inflammatory diseases are strongly associated with Major Histocompatibility Complex class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A29:02), ankylosing spondylitis (HLA-B27), Behçet's disease (HLA-B51), and psoriasis (HLA-C06:02). The endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 are also risk factors for these diseases. Since both enzymes are involved in the final processing steps of MHC-I ligands it is reasonable to assume that MHC-I-bound peptides play a significant pathogenetic role. Read More

View Article
October 2018
4 Reads

The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease.

Hum Immunol 2018 Nov 9. Epub 2018 Nov 9.

Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.

The oxytocinase subfamily of M1 aminopeptidases plays an important role in processing and trimming of peptides for presentation on major histocompatibility (MHC) Class I molecules. Several large-scale genomic studies have identified association of members of this family of enzymes, most notably ERAP1 and ERAP2, with immune-mediated diseases including ankylosing spondylitis, psoriasis and birdshot chorioretinopathy. Much is now known about the genetics of these enzymes and how genetic variants alter their function, but how these variants contribute to disease remains largely unresolved. Read More

View Article
November 2018
4 Reads

Geographic filling delay of the choriocapillaris in the region of dilated asymmetric vortex veins in central serous chorioretinopathy.

PLoS One 2018 9;13(11):e0206646. Epub 2018 Nov 9.

Department of Ophthalmology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Purpose: To investigate the correlation between geographic filling delays in the choriocapillaris using indocyanine green angiography (ICGA) images and dilated vortex veins in central serous chorioretinopathy (CSC).

Design: Observational case series.

Participants: Thirty-two eyes of 32 patients, 21 with acute and 11 with chronic CSC. Read More

View Article
November 2018
3 Reads

Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.

Medicine (Baltimore) 2018 Oct;97(43):e12885

Kudret Eye Hospital, Ankara, Turkey.

To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients.This retrospective study included 32 eyes of 32 consecutive patients with CSCR. There were 12 patients who presented with a spontaneous resolution of CSCR (Group 1) and 20 patients who were treated with ranibizumab for persistent subretinal fluid (SRF) (Group 2). Read More

View Article
October 2018
6 Reads

Choriocapillaris flow features and choroidal vasculature in the fellow eyes of patients with acute central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol 2018 Nov 5. Epub 2018 Nov 5.

Department of Ophthalmology, Korea University College of Medicine, 126-1 Anam-dong 5-ga, Sungbuk-gu, Seoul, 136-705, South Korea.

Purpose: The purpose of the study is to investigate the characteristics of choriocapillaris flow based on the underlying choroidal vasculature in fellow eyes with central serous chorioretinopathy (CSC).

Methods: We included 57 patients with CSC and normal controls. Characteristics of choriocapillaris flow were evaluated using swept-source optical coherence tomography (OCT) angiography. Read More

View Article
November 2018
4 Reads

Autoimmune thyroiditis and central serous chorioretinopathy may have a relation.

Med Hypotheses 2018 Dec 6;121:180-182. Epub 2018 Oct 6.

Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Saket Nagar, Bhopal, India. Electronic address:

Autoimmune thyroiditis (AT) is an important cause of hypothyroidism, and central serous chorioretinopathy (CSCR) is an independent disease of the choroid and retina that leads to accumulation of fluid beneath the retina. While AT has been associated with multiple antibodies, CSCR is still regarded as idiopathic despite extensive research. We hypothesize a causative association between these 2 conditions on the basis of our experience of a case where both CSCR and AT presented simultaneously and depicted a parallel course. Read More

View Article
December 2018
4 Reads

RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY.

Retin Cases Brief Rep 2018 Nov 2. Epub 2018 Nov 2.

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Hong Kong, China.

Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adolescent patients with any choroidal neovascularization etiology enrolled in the 12-month MINERVA study.

Methods: In the open-label, non-randomized study arm, ranibizumab 0. Read More

View Article
November 2018
4 Reads

Selective retina therapy: toward an optically controlled automatic dosing.

J Biomed Opt 2018 Nov;23(11):1-12

Medizinisches Laserzentrum Lübeck GmbH, Lübeck, Germany.

Selective retina therapy (SRT) targets the retinal pigment epithelium (RPE) with pulsed laser irradiation by inducing microbubble formation (MBF) at the intracellular melanin granula, which leads to selective cell disruption. The following wound healing process rejuvenates the chorio-retinal junction. Pulse energy thresholds for selective RPE effects vary intra- and interindividually. Read More

View Article
November 2018
2 Reads

Central serous chorioretinopathy in a patient of juxtapapillary excavation misdiagnosed as optic disc pit maculopathy.

BMJ Case Rep 2018 Nov 1;2018. Epub 2018 Nov 1.

Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

A 29-year-old healthy man had blurring of vision in the left eye for the past 2 months and was referred for the surgical management of optic disc pit maculopathy. Colour fundus examination and optical coherence tomography (OCT) revealed a large deep retinochoroidal excavation close to the temporal edge of the optic disc with an isolated central neurosensory detachment at the macula with underlying multiple small pigment epithelium detachments in the absence of retinoschisis. Fundus fluorescein angiography (FFA) confirmed the presence of multi-focal leakage at the macula and pooling into subretinal space in the form of a 'smoke-stack'. Read More

View Article
November 2018

Combined Argon Laser and Low Dose Acetylsalicylic acid in Treatment of Acute Central Serous Chorioretinopathy.

Med Hypothesis Discov Innov Ophthalmol 2018 ;7(3):126-132

Sohag Faculty of Medicine, Ophthalmology Department, Sohag, Egypt.

This study was designed to evaluate the efficacy of low-dose of oral acetylsalicylic acid (aspirin) with focal argon laser for the treatment of acute central serous chorioretinopathy (CSCR). In this prospective case-control study, 40 Patients with acute CSCR were classified randomly to two groups; group A with no treatment as the control group and group B with argon Laser in focal treatment once, followed by aspirin, 100 mg per day orally, with follow up period of 12 months by evaluation of visual acuity, and by Optical Coherence Tomography (OCT), every three months for one year. Patients in the second group treated with argon Laser and aspirin showed more clinically significant improvement in both visual acuity and OCT macular thickness by the end of the follow-up period when compared with the observational group. Read More

View Article
January 2018
1 Read

Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy?

Mult Scler Relat Disord 2018 Oct 2;27:147-150. Epub 2018 Oct 2.

Isfahan Eye Research Center (IERC), Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Ophthalmology, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan University of Medical Sciences, Isfahan, Iran; Isfahan Medical Students Research Center (IMSRC), Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address:

View Article
October 2018
3 Reads

Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy.

Acta Ophthalmol 2018 Oct 30. Epub 2018 Oct 30.

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Purpose: 'Type A' behavioural characteristics and psychosocial stress have traditionally been associated with chronic central serous chorioretinopathy (cCSC). However, a characteristical personality profile could not be identified in these patients and the presumed association with stress is subject to controversy, due to a lack of convincing studies using validated measuring instruments. In this study, we aimed to assess maladaptive personality traits, psychological morbidity and coping strategies in patients with cCSC, in order to identify potentially modifiable psychosocial aspects which could be used in support to current standard treatment. Read More

View Article
October 2018

Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.

Br J Ophthalmol 2018 Oct 24. Epub 2018 Oct 24.

INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, Université Paris Descartes, Centre de Recherche des Cordeliers, Paris, France

Aims: To evaluate the long-term oral mineralocorticoid receptor antagonist (MRa) treatment in chronic central serous chorioretinopathy (CSC).

Methods: Patients with chronic non-resolving CSC (defined as foveal subretinal fluid (SRF) lasting >4 months with retinal pigment epithelium (RPE) alterations) treated with MRa only (eplerenone or spironolactone) for at least 6 months were retrospectively included. Clinical and imaging characteristics were recorded during visits at baseline, 6, 12, 18 and 24  months. Read More

View Article
October 2018
4 Reads

Efficacy of oral rifampicin in chronic central serous chorioretinopathy.

Ther Adv Ophthalmol 2018 Jan-Dec;10:2515841418807130. Epub 2018 Oct 16.

Dr. Shroff's Charity Eye Hospital, New Delhi, India.

Objective: To evaluate the role of oral rifampicin in the management of chronic central serous chorioretinopathy.

Methods: Retrospective analysis of patients diagnosed with chronic central serous chorioretinopathy (duration >3 months) and treated with oral rifampicin 600 mg daily for a maximum period of 3 months was carried out. Baseline visual acuity, fundus fluorescein angiography, and optical coherence tomography were recorded and the patients were followed up. Read More

View Article
October 2018
5 Reads

Changes in Stromal and Luminal Areas of the Choroid in Pachychoroid Diseases: Insights Into the Pathophysiology of Pachychoroid Diseases.

Invest Ophthalmol Vis Sci 2018 Oct;59(12):4896-4908

Department of Ophthalmology, Konkuk University School of Medicine, Konkuk University Medical Center, Seoul, Republic of Korea.

Purpose: To evaluate and compare changes in choroidal vascular and stromal areas in patients with three major pachychoroid diseases for better insight into the pathophysiology of these diseases.

Methods: Eighty-six eyes of 86 patients (50 men and 36 women; mean age, 49.1 years) were evaluated, including 21 patients with chronic central serous chorioretinopathy (CSC), 14 with pachychoroid pigment epitheliopathy (PPE), 19 with pachychoroid neovasculopathy (PNV), 14 with myopic choroidal neovascularization (mCNV), and 18 controls. Read More

View Article
October 2018
5 Reads

Low-dose rifampin as maintenance therapy in chronic central serous chorioretinopathy.

Can J Ophthalmol 2018 Oct 13;53(5):e182-e183. Epub 2018 Feb 13.

University of Texas Medical Branch at Galveston, Galveston, TX; Houston Methodist Hospital, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX.

View Article
October 2018
6 Reads

Spectrum of choroidal neovascularisation associated with dome-shaped macula.

Br J Ophthalmol 2018 Oct 16. Epub 2018 Oct 16.

Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy

Aims: To investigate the clinical spectrum of choroidal neovascularisation (CNV) in patients with dome-shaped macula with the aid of multimodal imaging.

Methods: In this cross-sectional, retrospective, observational study, we reviewed charts and imaging studies of 144 eyes of 79 consecutive patients with dome-shaped macula evaluated at a tertiary referral centre, including optical coherence tomography angiography (OCTA), fluorescein angiography (FA) and indocyanine green angiography (ICGA). Three masked graders evaluated the prevalence and type of CNV. Read More

View Article
October 2018
12 Reads

Dark Spot in Fibrinous Central Serous Chorioretinopathy.

JAMA Ophthalmol 2018 Oct 11;136(10):e182924. Epub 2018 Oct 11.

Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article
October 2018
1 Read

Development of Central Serous Chorioretinopathy following Chalazion Removal with Intralesional Triamcinolone Injection: A Case Report.

Case Rep Ophthalmol 2018 Sep-Dec;9(3):416-420. Epub 2018 Sep 3.

Department of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, USA.

We report a case of central serous chorioretinopathy (CSC) that developed 1 month after an intralesional injection of triamcinolone acetonide that was administered during removal of a chalazion. The subretinal fluid and ipsilateral visual acuity (VA) worsened with initial observation. The edema resolved with verteporfin photodynamic therapy (PDT) 1 month after diagnosis, but VA did not improve during short-term follow-up. Read More

View Article
September 2018

Going green - treatment outcome and safety profile of chronic central serous chorioretinopathy treated with subthreshold green laser.

Clin Ophthalmol 2018 5;12:1963-1971. Epub 2018 Oct 5.

Department of Ophthalmology, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.

Aim: Subthreshold lasers have gained popularity in the treatment of chorioretinopathy central serous chorioretinopathy (CSCR) and yellow (577 nm) lasers have completely revolutionized the treatment. However, there is very little literature regarding the use of a more common and conventional - green (532 nm) subthreshold laser for the treatment of chronic CSCR. We report the use of green (532 nm) laser for the treatment of chronic CSCR and its outcome. Read More

View Article
October 2018
4 Reads

Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in non-resolving Central Serous Chorioretinopathy.

Am J Ophthalmol 2018 Oct 8. Epub 2018 Oct 8.

Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, AP-HP, Université Paris 7, Sorbonne Paris Cité, Paris, France.

Purpose: To assess the efficacy and safety of mineralocorticoid receptor antagonists (MRA) in the treatment of non-resolving central serous chorioretinopathy (CSC) and identify predictive factors of treatment response.

Design: Retrospective, multicenter, non-comparative, interventional case series.

Methods: Clinical and imaging data from consecutive patients with non-resolving CSC treated with eplerenone or spironolactone for 3-6 months between 2012 and 2016 were reviewed. Read More

View Article
October 2018
2 Reads

Genetic analysis of undiagnosed ataxia-telangiectasia-like disorders.

Brain Dev 2018 Oct 6. Epub 2018 Oct 6.

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address:

Objectives: Defects in DNA damage responses or repair mechanisms cause numerous rare inherited diseases, referred to as "DNA-repair defects" or "DNA damage deficiency", characterized by neurodegeneration, immunodeficiency, and/or cancer predisposition. Early accurate diagnosis is important for informing appropriate clinical management; however, diagnosis is frequently challenging and can be delayed, due to phenotypic heterogeneity. Comprehensive genomic analysis could overcome this disadvantage. Read More

View Article
October 2018
1 Read

GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY.

Retina 2018 Oct 8. Epub 2018 Oct 8.

Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.

Purpose: To investigate genetic associations in white patients with acute central serous chorioretinopathy (aCSC) and to assess genetic differences between aCSC and chronic CSC (cCSC).

Methods: A total of 135 aCSC patients, 272 cCSC patients, and 1,385 control individuals were included. Eight single nucleotide polymorphisms were genotyped for ARMS2 (rs10490924), CFH (rs800292, rs1061170, rs1065489, rs1329428, rs2284664, rs3753394), and NR3C2 (rs2070951). Read More

View Article
October 2018
2 Reads

Acute syphilitic posterior placoid chorioretinopathy mimicking central serous chorioretinopathy: A case report.

Taiwan J Ophthalmol 2018 Jul-Sep;8(3):176-178

Department of Ophthalmology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

A 51-year-old man had experienced declining visual acuity for 4 months. His best-corrected visual acuity was 20/40 in both eyes. Ophthalmoscopic examination showed a yellowish placoid lesion over the macular area, and spectral-domain optical coherence tomography (SD-OCT) revealed subretinal fluid accumulation in the left eye, which resembled that seen with central serous chorioretinopathy (CSCR). Read More

View Article
October 2018
3 Reads

DEVELOPMENT OF PACHYCHOROID PIGMENT EPITHELIOPATHY AND TRANSFORMATION TO CENTRAL SEROUS CHORIORETINOPATHY AFTER INTRAVITREAL DEXAMETHASONE IMPLANTATION.

Retin Cases Brief Rep 2018 Sep 26. Epub 2018 Sep 26.

Istanbul Retina Institute, Istanbul, Turkey.

Purpose: To report first case of sequential development of pachychoroid pigment epitheliopathy (PPE) and central serous chorioretinopathy (CSC) after repeated intravitreal dexamethasone implantations for diabetic macular edema treatment.

Methods: We present a case of a 54-year-old man having intravitreal dexamethasone implant for bilateral diabetic macular edema.

Results: We observed development of pachychoroid pigment epitheliopathy, seen as a small pigment epithelial detachment on optical coherence tomography after a fourth dexamethasone implantation. Read More

View Article
September 2018
7 Reads

Morphologic features of large choroidal vessel layer: age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol 2018 Dec 27;256(12):2309-2317. Epub 2018 Sep 27.

Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #222 Banpodae-ro, Seocho-gu, Seoul, 06591, Republic of Korea.

Purpose: To compare choroidal vascular characteristics of age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy (CSC) by qualitative and quantitative analyses using swept-source en face optical coherence tomographic (OCT) images.

Methods: Eyes with non-neovascular AMD (n = 32), neovascular AMD (n = 30), thick and thin choroid PCV (n = 33 and 27), and CSC (n = 34) were enrolled. Subfoveal choroidal thickness (SFCT) and the presence and patterns of pachyvessels were assessed. Read More

View Article
December 2018

[Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists].

Ophthalmologe 2018 Sep 25. Epub 2018 Sep 25.

Klinik für Augenheilkunde, Medizinische Fakultät, Universitätsklinikum Freiburg, Killianstraße 5, 79106, Freiburg, Deutschland.

Background: Over 3 years have passed since the last publication on the therapeutic principle "Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy" by Maier et al., and numerous new studies have been published on the topic. The aim of this work is to provide an update on the current literature and reevaluate the role of mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy (CSC). Read More

View Article
September 2018

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature.

Int J Retina Vitreous 2018 19;4:33. Epub 2018 Sep 19.

12nd Department of Ophthalmology, National and Kapodistrian University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342 Athens, Greece.

Purpose: The purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR).

Methods: A comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies using spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates. Read More

View Article
September 2018